About Us
Yibing Shan, Founding Managing Director
Dr. Yibing Shan is a world leader in the field of computational drug discovery. He has been a founding member of D. E. Shaw Research and played a key role in the conception and design of Anton Specialized Supercomputer for molecular dynamics simulations and was twice a co-recipient of the Association of Computing Machinery (ACM) Gordon Bell Prize in 2006 and 2009. The Gaussian Split Ewald algorithm he developed is a key design feature of Anton Supercomputers.
Yibing conceived the “swimming” simulations of biomolecular association and developed it into a simulation tool that has become integral to a number of state-of-the-art drug discovery platforms. In search for optimal strategies to apply molecular dynamics simulations to enable and expedite drug discovery, he conducted drug discovery programs targeting Mcl-1, K-Ras and Nedd4 in his 18-year tenure in D. E. Shaw Research. Since then, his research pivoted to computational structural biology and computational chemistry. His team pioneered simulation-based structural elucidation of large functional assemblies of proteins, which includes EGFR, JAK2, and Raf kinases, plexins, and Rho and Ras small GTPases.
Yibing Shan is also the founding managing director of Antidote Health Foundation for Cure of Cancer and Chief Computational Scientist of BAKX Therapeutics Inc, a portfolio company of AB Magnitude Ventures Group. He earned his A.B. in engineering physics from Shanghai University of Science and Technology, a M.S. in computer science and a PhD in biophysics from Drexel University.
Social Media and Links
